Galera Therapeutics’ Rucosopasem Shows Early Anti-Cancer Activity, Pulmonary Function Preservation
Galera Therapeutics Inc (NASDAQ:GRTX) announced results from the open-label Phase 1 stage of the GRECO-1 trial of rucosopasem in combination with…
B of A Securities Downgrades Galera Therapeutics to Underperform, Announces $2 Price Target
B of A Securities analyst Tazeen Ahmad downgrades Galera Therapeutics (NASDAQ:GRTX) from Neutral to Underperform and announces $2 price target.
Galera Announces Oral Presentation At 2022 American Society Of Clinical Oncology Annual Meeting Detailing Results From Phase 3 ROMAN Trial Of Avasopasem
Galera Therapeutics, Inc. (NASDAQ:GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform
110 Biggest Movers From Friday
Gainers
ShiftPixy, Inc. (NASDAQ: PIXY) shares jumped 154.9% to close at $0.51. ShiftPixy reported board approval special dividend to shareholders in form of common shares of Industrial Human Capital.
12 Health Care Stocks Moving In Wednesday’s After-Market Session
Gainers
Greenwich LifeSciences (NASDAQ:GLSI) stock moved upwards by 9.6% to $23.84 during Wednesday's after-market session. The market value of their outstanding shares is at $312.8 million. As per the press release, Q4 earnings came out 2 days ago.
How Is The Market Feeling About Galera Therapeutics Inc?
Galera Therapeutics Inc's (NASDAQ:GRTX) short percent of float has risen 14.61% since last its last report. The company recently reported that it has 739.10 thousand shares sold short, which is 7.06% of all regular shares that are available for trading.